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Based on some publications that associate SARS-CoV-2 infection with the use of anti-hypertensive 
drug groups such as angiotensin-converting-enzyme inhibitors (e.g. enalapril) or angiotensin II 
receptor blockers (e.g. losartan), many patients from South America, Central America or Spain, 
have stopped or intend to interrupt their treatments with these drugs. Hence, it may exist ominous 
consequences due to this drop out. For this reason, it is necessary to quickly warn about this 
situation and the risks associated with it.
 We would like to contribute with some reflections 
regarding the association of SARS-CoV-2 infection, 
hypertension and antihypertensive drugs. 
 It is a fact that SARS-CoV-2 enters to the cells by the 
same route as the SARS-CoV that is, through a binding 
with the angiotensin II converting enzyme (ACE-II) (1-
4). Cells with large amounts of ACE-II are present in the 
salivary glands of the mouth, along all the respiratory 
tract, epithelial cells of the lung, intestine, kidney, and 
blood vessels (5). ACE-II expression increases when 
patients are treated with drugs that inhibits this enzyme or 
with angiotensin II receptor blockers (ATII-RB) (5). This 
is due to the properties of both groups to significantly 
increase mRNA expression for ACE, increasing in this 
way the amount of enzyme available in the cells (6). 
Consequently, some authors hypothesize that ACE-II or 
ATII-RB groups, increasing the expression of ACE II 
in some cells (particularly alveoli) may rise the risk of 
infection with SARS-CoV-2 (4-6). Likewise, 2 studies 
in patients with confirmed coronavirus disease 2019 
(COVID-19), showed that up to 30% of people affected 
had chronic arterial hypertension disease hypothesizing 
that hypertension may favor infection or aggravation of 
COVID-19 symptoms (7-9). 
 From these data we can conclude that there is 
a "potential/theoretical" risk that drugs from the 
ACE inhibitors group (such as enalapril, ramipril, 
captopril, and lisinopril) and ATII-RB (such as losartan, 
candesartan, valsartan, ibersartan, and telmisartan) 
may favor the internalization of COVID-19 inside the 
cell. However, we must recognize that the scientific 
foundation of this theory is very weak to date (10). 
About the reports associating hypertension with 
COVID-infection, it could be said that although 23 to 
30% of the patients hospitalized because of the virus, 
had hypertension, it should be recognized that the 
prevalence of hypertension in adults is around that same 
percentage; so, this epidemiological association is clearly 
objectionable.
 The abrupt drop-out of anti-hypertensive treatment 
could be associated with serious risks such as acute 
myocardial infarction (AMI), stroke and death from 
cardiovascular causes. So, withdraw of hypertension 
therapy, might cause even more morbidity and mortality 
than COVID-19 itself. If patients or their doctors wish 
to change ACEII-ATII-RB therapeutics, it would be time 
to remember that other anti-hypertensive groups like 
thiazide diuretics are a rational, effective, cheap and safe 
option.
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